Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
Pituitary. 2017 Dec;20(6):676-682. doi: 10.1007/s11102-017-0833-7.
Internal carotid artery (ICA) aneurysms have rarely been found in association with marked hyperprolactinemia in the absence of prolactinoma; the cause of hyperprolactinemia has never been investigated. We aimed to determine if the observed hyperprolactinemia is due to a vascular-derived or known prolactin secretagogue from the injured ICA, analogous to pregnancy-associated hyperprolactinemia putatively due to placental factors.
We conducted a case series and literature review of individuals with severe hyperprolactinemia in association with ICA aneurysms. In two affected patients at our institutions, we performed RT-PCR and ELISA of prolactin secretagogues that are produced by vascular tissue and/or upregulated in pregnancy: AGT (encoding angiotensinogen), TAC1 (encoding substance P), HDC (encoding the enzyme responsible for conversion of histidine to histamine), and prolactin-releasing hormone (PRLH). Patient blood samples were compared to pregnancy blood samples (positive controls) and middle-aged male blood samples (negative controls).
Two men presented with serum prolactin >100-fold normal associated with cavernous ICA aneurysms and no pituitary adenoma. Aneurysm stenting in one man more than halved his serum prolactin. In both men, dopamine agonist therapy markedly reduced serum prolactin. RT-PCR and ELISA showed no differences between patients and controls in AGT, TAC1 or HDC expression or PRLH titre, respectively. Literature review revealed 11 similar cases.
We propose the term 'vasculogenic hyperprolactinemia' to encompass the hyperprolactinemia associated with ICA aneurysms. This may be mediated by an endothelial factor capable of paracrine stimulation of lactotrophs; however, angiotensin II, substance P, histamine and PRLH appear unlikely to be causative.
在不存在泌乳素瘤的情况下,罕见发现与明显高泌乳素血症相关的颈内动脉(ICA)动脉瘤;高泌乳素血症的原因从未被研究过。我们旨在确定观察到的高泌乳素血症是否是由于血管来源的或已知的损伤 ICA 来源的泌乳素分泌刺激物引起的,类似于推测由于胎盘因素引起的妊娠相关性高泌乳素血症。
我们对伴有 ICA 动脉瘤的严重高泌乳素血症患者进行了病例系列和文献回顾。在我们机构的两名受影响的患者中,我们进行了血管组织产生和/或妊娠时上调的泌乳素分泌刺激物的 RT-PCR 和 ELISA 检测:AGT(编码血管紧张素原)、TAC1(编码 P 物质)、HDC(编码将组氨酸转化为组胺的酶)和泌乳素释放激素(PRLH)。患者血液样本与妊娠血液样本(阳性对照)和中年男性血液样本(阴性对照)进行了比较。
两名男性的血清泌乳素水平高于正常水平的 100 倍,伴有海绵窦 ICA 动脉瘤,且无垂体腺瘤。一名男性的动脉瘤支架置入术使他的血清泌乳素减少了一半以上。在这两名男性中,多巴胺激动剂治疗显著降低了血清泌乳素水平。RT-PCR 和 ELISA 显示,患者与对照组在 AGT、TAC1 或 HDC 表达或 PRLH 滴度方面均无差异。文献回顾发现了 11 例类似病例。
我们提出了“血管源性高泌乳素血症”一词来包含与 ICA 动脉瘤相关的高泌乳素血症。这可能是由一种能够旁分泌刺激催乳素细胞的内皮因子介导的;然而,血管紧张素 II、P 物质、组胺和 PRLH 似乎不太可能是致病因素。